Dan McKellar’s headset count: 1 broken, 3 screamed into, 0 solutions found. Langi Gleeson: Carried the team on his back, ...

In Netflix’s new mini-series "Adolescence," which follows a 13-year-old boy accused of murdering his classmate after becoming radicalized online, characters say Jamie Miller (Owen Cooper) is ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs. By Gina Kolata and Rebecca Robbins A daily pill may be as ...

If you apply those same criteria to the Beats Pill and the JBL Flip 7, the Pill comes out on top. It has a cleaner, better balanced sound signature, and it will happily ride all the way to its maximum ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

Lilly says April 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients ...

By Rebecca Robbins and Gina Kolata Encouraging clinical trial results announced on Thursday stand to open up a huge market for a convenient daily pill to treat obesity and diabetes. The ...

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight ... which pushed Lilly’s shares up as much as 17%, the most intraday since August 2023.

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved. An experimental once-daily pill appears to ...